Navigation Links
Replidyne Announces 2007 Fourth Quarter and Full Year Results
Date:2/26/2008

LOUISVILLE, Colo., Feb. 26 /PRNewswire-FirstCall/ -- Replidyne, Inc. (Nasdaq: RDYN) today announced its financial results for the fourth quarter and full year ended December 31, 2007.

Replidyne reported a net loss of $16.9 million for the fourth quarter ended December 31, 2007, or a net loss per basic and diluted common share of $0.63 per share, compared to a net loss of $9.6 million, or $0.36 per basic and diluted common share, for the quarter ended December 31, 2006. For the year ended December 31, 2007, Replidyne reported net income of $7.7 million, or $0.29 per share basic common share and $0.28 per diluted common share, compared to a net loss of $29.2 million, or $2.49 per basic and diluted common share, for the year ended December 31, 2006. Net income for the current year was due to revenue recognized upon termination of the company's commercialization and development agreement for faropenem medoxomil (faropenem) with Forest Laboratories (Forest) in May 2007. Cash, cash equivalents and short-term investments at December 31, 2007 totaled $90.3 million.

"At the end of 2007, we streamlined our operations by restructuring the organization and re-prioritizing our research and development pipeline. In 2008, we continue to focus on our main objectives," said Kenneth J. Collins, Replidyne's President and CEO. "Securing a partner for the faropenem program remains a top priority. We intend to advance our Clostridium difficile program and file an IND by the end of the year. Also by the end of the year, we expect to identify an IND candidate from our DNA replication inhibition program. Finally, we will continue to seek strategic alternatives that augment our pipeline and add value."

Revenue for the year ended December 31, 2
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Replidyne to Announce Third Quarter 2007 Earnings
2. Replidyne to Report 2007 Fourth Quarter and Year-End Earnings
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Ames, IA (PRWEB) April 16, 2015 ... (CAST) announces that the prestigious 2015 Borlaug CAST ... honored faculty member at Tuskegee University in Alabama. ... by written material; public presentations; and/or the use ... excels in all three areas. As a specialist ...
(Date:4/16/2015)... 16, 2015 /CNW/ - Bioenterprise Corporation is pleased to announce ... Charlottetown , PEI.  Bioenterprise has established ... ADAPT Council for the commercialization of agricultural technologies and ... with PEI ADAPT.  They have been at the heart ... decade," explains Dave Smardon , President & CEO ...
(Date:4/16/2015)... Calif. , April 16, 2015  Scientists from ... "New Drugs on the Horizon," at the American Association ... Philadelphia, PA on Sunday, April 19, 2015 ... Ph.D., Cleave,s Director of Biology, will present new in ... a first-in-class, oral inhibitor of p97, a critical enzyme ...
(Date:4/16/2015)... Columbia and MENLO PARK, Calif. ... Inc. (OTCQX: DMPI) (DelMar and the Company), a ... therapies in new orphan drug indications, today announced that ... added as a clinical trial site for the ongoing, ... refractory glioblastoma multiforme (GBM), the most common and deadly ...
Breaking Biology Technology:The 2015 Borlaug CAST Communication Award Goes to Channapatna Prakash 2Bioenterprise Corporation Expands into the Maritimes 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5
... HEIGHTS, N.J., Nov. 26 Genta,Incorporated (Nasdaq: ... and,Chief Executive Officer, Dr. Raymond P. Warrell, Jr., ... activities at the Lazard Capital,Markets 4th Annual Healthcare ... at 8:00 am EST at the New York ...
... Inverness Medical,Innovations, Inc. (AMEX: IMA ) ... agreement to acquire ParadigmHealth, Inc. ParadigmHealth,headquartered in New ... care,and disease management services for acutely ill and ... patients., Commenting on the agreement, Ron Zwanziger, ...
... Unique Buying Opportunity Presented, CHARLES TOWN, ... (Pink Sheets: RBRM), a provider of treatment ... announced,it has successfully concluded analysis of the ... it to the Board of Directors., ...
Cached Biology Technology:Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference 2Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference 3Inverness Medical Innovations Agrees to Acquire ParadigmHealth 2Inverness Medical Innovations Agrees to Acquire ParadigmHealth 3ReBuilder Medical Technologies, Inc.'s Recent Stock Price Volatility Explained 2
(Date:3/23/2015)... --  HOYOS Labs , a leading global authentication infrastructure ... Company will demonstrate multiple biometrics-based technologies under its identity ... on March 23 through 25, 2015, in ... IEEE Biometric Open Protocol Standard; free biometrics-based consumer app, ... system. BOPS was invented by HOYOS Labs and contributed ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for ...
(Date:3/18/2015)... March 18, 2015 As mobile payments ... revolutionary smart wallets and apps continue to be introduced into ... in the mobile payment industry in focus today are:  NXT-ID, ... (NYSE: BABA ), Apple Inc. (NASDAQ: ... Facebook Inc. (NASDAQ: FB ) NXT-ID, ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... to spray venom into eyes of potential attackers. A ... reveals how these snakes maximize their chances of ... a bit of a misnomer. Cobras don,t actually "spit" ... of the Anatomical Laboratory in the Department of Physical ...
... researchers have identified a cellular mechanism that could someday ... Stephen Helfand and Nicola Neretti and others adds another ... biology, molecular biology, cell biology and biochemistry, first discovered ... the Indy ("I,m Not Dead Yet") gene that can ...
... NY, January 22, 2009--Biotechnology companies are building on ... the past decade and are expected to drive ... reports Genetic Engineering and Biotechnology News ... offers a number of advantages, including reducing reagent ...
Cached Biology News:Here's venom in your eye: Spitting cobras hit their mark 2Scientists unlock possible aging secret in genetically altered fruit fly 2GEN reports on growing reliance on microfluidics technology 2
Phospho-SEK1/MKK4 (Thr261) Antibody...
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Phospho-FADD (Ser194) Antibody (Human Specific)...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Biology Products: